139 related articles for article (PubMed ID: 37876093)
1. Betibeglogene Autotemcel; A New Hope For Transfusion Dependent Beta-Thalassaemia.
Wally HT; Zulfi MH; Jilani ES
J Pak Med Assoc; 2023 Oct; 73(10):2129-2130. PubMed ID: 37876093
[No Abstract] [Full Text] [Related]
2. Case study of betibeglogene autotemcel gene therapy in an adult Greek patient with transfusion-dependent β-thalassaemia of a severe genotype.
Constantinou V; Papayanni PG; Mallouri D; Batsis I; Bouinta A; Papadopoulou D; Papadimitriou V; Kammenou M; Pantelidou D; Sotiropoulos D; Sakellari I; Anagnostopoulos A; Yannaki E
Br J Haematol; 2022 Mar; 196(6):1401-1404. PubMed ID: 34957544
[No Abstract] [Full Text] [Related]
3. The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia.
Lancaster V; Richardson M; Beaudoin FL; Synnott PG; Rind DM; Herce-Hagiwara B; Campbell JD; Pearson SD
J Manag Care Spec Pharm; 2022 Nov; 28(11):1316-1320. PubMed ID: 36282936
[No Abstract] [Full Text] [Related]
4. Betibeglogene Autotemcel Gene Therapy for Non-β
Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
[TBL] [Abstract][Full Text] [Related]
5. In brief: Casgevy for beta thalassemia.
Med Lett Drugs Ther; 2024 May; 66(1702):79. PubMed ID: 38696313
[No Abstract] [Full Text] [Related]
6. Drug product attributes predict clinical efficacy in betibeglogene autotemcel gene therapy for β-thalassemia.
Whitney D; Shestopalov I; Fincker M; d'Anjou M; Kral K; Gayron M; Pierciey FJ; Colvin RA
Mol Ther Methods Clin Dev; 2023 Dec; 31():101155. PubMed ID: 38074412
[No Abstract] [Full Text] [Related]
7. Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies.
Taher AT; Bou-Fakhredin R; Kattamis A; Viprakasit V; Cappellini MD
Expert Rev Hematol; 2021 Oct; 14(10):897-909. PubMed ID: 34493145
[TBL] [Abstract][Full Text] [Related]
8. Novel sequence insertion in a Mâori patient with transfusion-dependent beta-thalassaemia.
Blacklock HA; Case J; Chan T; Raizis T; Doocey R; Fellowes A; Royle G; Jackson S; Brennan S; George P
Br J Haematol; 2005 Nov; 131(3):400-2. PubMed ID: 16225661
[TBL] [Abstract][Full Text] [Related]
9. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
10. Medical management of beta-thalassaemia without blood transfusion: a myth or a reality?
Shamsi T; Ansari S
J Pak Med Assoc; 2013 Mar; 63(3):304-5. PubMed ID: 23914624
[No Abstract] [Full Text] [Related]
11. Adrenal insufficiency is prevalent in HbE/β-thalassaemia paediatric patients irrespective of their clinical severity and transfusion requirement.
Nakavachara P; Viprakasit V
Clin Endocrinol (Oxf); 2013 Dec; 79(6):776-83. PubMed ID: 23634994
[TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype diversity of beta-thalassemia in Malaysia: treatment options and emerging therapies.
George E; Ann TJ
Med J Malaysia; 2010 Dec; 65(4):256-60. PubMed ID: 21901940
[TBL] [Abstract][Full Text] [Related]
13. Beta-thalassemia and the advent of new interventions beyond transfusion and iron chelation.
Chauhan W; Shoaib S; Fatma R; Zaka-Ur-Rab Z; Afzal M
Br J Clin Pharmacol; 2022 Aug; 88(8):3610-3626. PubMed ID: 35373382
[TBL] [Abstract][Full Text] [Related]
14. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia.
Biswas S; Nag A; Ghosh K; Ray R; Roy K; Bandyopadhyay A; Bhattacharyya M
Ann Hematol; 2019 Feb; 98(2):289-299. PubMed ID: 30413899
[TBL] [Abstract][Full Text] [Related]
15. Wild-type HIV infection after treatment with lentiviral gene therapy for β-thalassemia.
Hongeng S; Anurathapan U; Songdej D; Phuphuakrat A; Jongrak K; Parsons G; Deary B; Bonner M; Veres G; Asmal M
Blood Adv; 2021 Jul; 5(13):2701-2706. PubMed ID: 34196676
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy: Targeting β-thalassaemia.
Persons DA
Nature; 2010 Sep; 467(7313):277-8. PubMed ID: 20844523
[No Abstract] [Full Text] [Related]
17. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.
Cavazzana-Calvo M; Payen E; Negre O; Wang G; Hehir K; Fusil F; Down J; Denaro M; Brady T; Westerman K; Cavallesco R; Gillet-Legrand B; Caccavelli L; Sgarra R; Maouche-Chrétien L; Bernaudin F; Girot R; Dorazio R; Mulder GJ; Polack A; Bank A; Soulier J; Larghero J; Kabbara N; Dalle B; Gourmel B; Socie G; Chrétien S; Cartier N; Aubourg P; Fischer A; Cornetta K; Galacteros F; Beuzard Y; Gluckman E; Bushman F; Hacein-Bey-Abina S; Leboulch P
Nature; 2010 Sep; 467(7313):318-22. PubMed ID: 20844535
[TBL] [Abstract][Full Text] [Related]
18. Alpha Globin Gene Mutation: A Major Determinant of Hydroxyurea Response in Transfusion-Dependent HbE-β-Thalassaemia.
Biswas S; Ray R; Roy K; Bandyopadhyay A; Ghosh K; Bhattacharyya M
Acta Haematol; 2019; 142(3):132-141. PubMed ID: 31352439
[TBL] [Abstract][Full Text] [Related]
19. Thalassaemia intermedia: the role of erythroexchange in the treatment of an indolent wound.
Pignatti M; Govoni M; Graldi G; Pacchioni L; De Santis G; Borgna C
Blood Transfus; 2014 Jan; 12(1):124-6. PubMed ID: 24333066
[No Abstract] [Full Text] [Related]
20. Iron overload is associated with low anti-müllerian hormone in women with transfusion-dependent β-thalassaemia.
Chang HH; Chen MJ; Lu MY; Chern JP; Lu CY; Yang YL; Jou ST; Lin DT; Yang YS; Lin KH
BJOG; 2011 Jun; 118(7):825-31. PubMed ID: 21401854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
